Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas

Modern Pathology

Volumn 28, Issue 11, 2015, Pages 1404-1414

  Saâda Bouzid, Esma ^a,b,c   Burel Vandenbos, Fanny ^a   Ranchère Vince, Dominique ^d   Birtwisle Peyrottes, Isabelle ^c   Chetaille, Bruno ^e   Bouvier, Corinne ^f   Château, Marie Christine ^g   Peoc'H, Michel ^h   Battistella, Maxime ⁱ   Bazin, Audrey ^a   Gal, Jocelyn ^c   Michiels, Jean François ^a   Coindre, Jean Michel ^j   Pedeutour, Florence ^a,b   Bianchini, Laurence ^a,b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f TIMONE HOSPITAL   (France)

^g CENTRE VAL D AURELLE   (France)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j INSTITUT BERGONIÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; HIGH MOBILITY GROUP A2 PROTEIN; ONCOPROTEIN; TUMOR MARKER;

5' UNTRANSLATED REGION; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CDK4 GENE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DEDIFFERENTIATED LIPOSARCOMA; DISTANT METASTASIS; EXON; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; HIGH MOBILITY GROUP A2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JUN GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SHORT TERM SURVIVAL; TUMOR GENE; TUMOR RECURRENCE; WELL DIFFERENTIATED LIPOSARCOMA; CASE REPORT; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIPOSARCOMA; MIDDLE AGED; MORTALITY; ONCOGENE; PATHOLOGY; PROGNOSIS; SOFT TISSUE TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE 4; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, JUN; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LIPOSARCOMA; MALE; MIDDLE AGED; ONCOGENE PROTEIN P65(GAG-JUN); PROGNOSIS; SOFT TISSUE NEOPLASMS;

EID: 84946497777     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.96     Document Type: Article

References (38)

1. Dei Tos AP, Pedeutour F. Well-differentiated liposarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW et al. (eds). WHO Classification of Tumors of Soft Tissue and Bone, 4th edn. International Agency for Research on Cancer (IARC): Lyon, France, 2013, pp 33-36.
2. Pedeutour F, Forus A, Coindre JM et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30-41.
3. Crago AM, Socci ND, DeCarolis P et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res 2012;18:1334-1340.
4. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011;23:373-378.
5. Italiano A, Bianchini L, Keslair F et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122: 2233-2241.
6. Tap WD, Eilber FC, Ginther C et al. Evaluation of welldifferentiated/ de-differentiated liposarcomas by highresolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 2011;50:95-112.
7. Ragazzini P, Gamberi G, Pazzaglia L et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol 2004;19:401-411.
8. Ray-Coquard I, Blay JY, Italiano A et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;13: 1133-1140.
9. Italiano A, Bianchini L, Gjernes E et al. Clinical and biological significance of CDK4 amplification in welldifferentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009;15:5696-5703.
10. Wang X, Asmann YW, Erickson-Johnson MR et al. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in welldifferentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer 2011;50:849-858.
11. Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008;32: 289-305.
12. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 1999;19:3246-3256.
13. Chibon F, Mariani O, Derre J et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer 2004;40:32-37.
14. Mariani O, Brennetot C, Coindre JM et al. JUN oncogene amplification and overexpression block adipocytic differentiation in. Cancer Cell 2007; 11:361-374.
15. Snyder EL, Sandstrom DJ, Law K et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009;218: 292-300.
16. Nord KH, Macchia G, Tayebwa J et al. Integrative genome and transcriptome analyses reveal two distinct types of ring chromosome in soft tissue sarcomas. Hum Mol Genet 2014;23:878-888.
17. Coindre JM. Histologic grading of adult soft tissue sarcomas. Verh Dtsch Ges Pathol 1998;82:59-63.
18. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
19. Bianchini L, Saada E, Gjernes E et al. Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer 2011;50:442-455.
20. Binh MB, Sastre-Garau X, Guillou L et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29:1340-1347.
21. Dei Tos AP, Doglioni C, Piccinin S et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumors. J Pathol 2000;190:531-536.
22. Marino-Enriquez A, Fletcher CD, Dal Cin P et al. Dedifferentiated liposarcoma with 'homologous' lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol 2010;34:1122-1131.
23. Dreux N, Marty M, Chibon F et al. Value and limitation of immunohistochemical expression of HMGA2 in mesenchymal tumors: about a series of 1052 cases. Mod Pathol 2010;23:1657-1666.
24. Meyer B, Loeschke S, Schultze A et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinogen 2007;46:503-511.
25. Miyazawa J, Mitoro A, Kawashiri S et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64: 2024-2029.
26. Califano D, Pignata S, Losito NS et al. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol 2014;229:53-59.
27. Zhou X, Benson KF, Ashar HR et al. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-774.
28. Battista S, Fidanza V, Fedele M et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999;59: 4793-4797.
29. Hirning-Folz U, Wilda M, Rippe V et al. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350-357.
30. Franco R, Esposito F, Fedele M et al. Detection of highmobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumors. J Pathol 2008;214:58-64.
31. Akai T, Ueda Y, Sasagawa Y et al. High mobility group I-C protein in astrocytoma and glioblastoma. Pathol Res Pract 2004;200:619-624.
32. Fedele M, Berlingieri MT, Scala S et al. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 1998;17: 413-418.
33. Taylor BS, DeCarolis PL, Angeles CV et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011;1:587-597.
34. Sun T, Fu M, Bookout AL et al. MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol Endocrinol 2009;23:925-931.
35. Narita M, Krizhanovsky V, Nunez S et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006;126: 503-514.
36. Horvai AE, DeVries S, Roy R et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 2009;22: 1477-1488.
37. Chibon F, Mariani O, Derre J et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002;139: 24-29.
38. Toulmonde M, Le Cesne A, Piperno-Neumann S et al. Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. Ann Oncol 2015;26:1465-1470.